CG Oncology (CGON) Stock: Buy, Sell, or Hold?
CGON - CG Oncology, Inc. Common stock
$68.35
-2.54 (-3.58%)
▼
5d:
-0.6%
30d:
-9.9%
90d:
-2.86%
HOLD
MODERATE Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 13, 2026
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Oct 1, 2026 at $70.19 · last confirmed Oct 1, 2026
Strength: 6.7/10
Get Alerted When CGON Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CGON shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: CGON shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: CGON is currently trading at $68.35, which is considered oversold relative to its 30-day fair value range of $71.52 to $77.84.
Technical Outlook: Technically, CGON is in a uptrend. Immediate support is located at $66.01, while resistance sits at $80.63. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: The stock scores a mixed 58/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $91.08 (+33.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CGON is in a uptrend. Immediate support is located at $66.01, while resistance sits at $80.63. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: The stock scores a mixed 58/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $91.08 (+33.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$71.52 -
$77.84
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (58/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.6%)
- BULLISH: Trading 33.3% below Wall St target ($91.08)
- NEUTRAL: Bottoming setup forming (58/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$71.52 -
$77.84
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$66.01
Resistance Level
$80.63
Current Trend
Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-22.63
Wall Street Target
$91.08
(+33.3%)
Revenue Growth (YoY)
1982.7%
Share & Embed Analysis
Last updated: October 01, 2026 10:22 PM ET
Data refreshes hourly during market hours. Next update: 11:22 PM
Data refreshes hourly during market hours. Next update: 11:22 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CGON showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
James Mulay
SELL
15600 shares
2026-04-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$92 | 59 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 63 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 73 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 61 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 44 HOLD |
